Introduction
The growth hormone axis is a complex endocrine signaling system involving communication between the hypothalamus, pituitary gland, and peripheral tissues.
Within this system, growth hormone-releasing hormone (GHRH) plays an important role in regulating growth hormone secretion through specialized receptors located on pituitary somatotroph cells.
CJC-1295 (No DAC) is a synthetic peptide commonly associated with laboratory research investigating this signaling pathway. Understanding its molecular characteristics requires examining native GHRH, synthetic analogs, receptor activation, and structural modifications.
What Is CJC-1295 (No DAC)?
CJC-1295 (No DAC) is a commercial designation commonly used for a modified analog of the first 29 amino acids of growth hormone-releasing hormone. This peptide is frequently described as Modified GRF (1–29).
The compound originally described in published CJC-1295 clinical research contains a Drug Affinity Complex (DAC) modification designed to prolong its interaction with circulating albumin. The compound commonly marketed as CJC-1295 (No DAC) lacks that albumin-binding modification.
These compounds should not be treated as chemically identical or assumed to share the same pharmacokinetic characteristics. For research documentation, the exact peptide sequence, molecular mass, and chemical modifications are more informative than the commercial name alone.
Understanding Growth Hormone-Releasing Hormone
Growth hormone-releasing hormone is a naturally occurring peptide hormone produced primarily in the hypothalamus. Its principal endocrine function involves stimulating growth hormone secretion from specialized cells in the anterior pituitary gland.
GHRH interacts with the growth hormone-releasing hormone receptor (GHRH-R), a G protein-coupled receptor. When activated, the receptor initiates intracellular signaling processes contributing to regulation of growth hormone synthesis and secretion.
How Does GHRH Receptor Signaling Work?
The GHRH receptor is located on the surface of pituitary somatotroph cells. A simplified representation of the pathway includes:
1. A GHRH-related ligand interacts with the GHRH receptor.
2. Receptor activation stimulates G protein-mediated signaling.
3. Intracellular cyclic adenosine monophosphate (cAMP) concentrations increase.
4. Protein kinase A and other downstream components become involved.
5. Cellular processes associated with growth hormone synthesis and secretion are regulated.
Researchers studying GHRH analogs investigate how structural differences may influence receptor interaction and downstream signaling behavior.
What Does No DAC Mean?
DAC stands for Drug Affinity Complex. The modification incorporated into the originally studied CJC-1295 molecule was designed to facilitate interaction with circulating albumin, an abundant blood plasma protein.
Association with albumin can alter the distribution and persistence of certain compounds. The No DAC designation indicates that this particular albumin-binding modification is absent. Results obtained with DAC-containing CJC-1295 should not automatically be attributed to the DAC-free analog.
How Is CJC-1295 (No DAC) Different From Tesamorelin?
Tesamorelin and the peptide commonly marketed as CJC-1295 (No DAC) are both associated with GHRH receptor signaling but are distinct molecular entities.
Tesamorelin is a synthetic analog of human GHRH containing a modified 44-amino-acid sequence. CJC-1295 (No DAC), as commonly described commercially, is based on a modified 29-amino-acid GHRH fragment. Findings from studies involving one compound should not automatically be generalized to the other.
Research Applications and Scientific Questions
Laboratory investigations involving GHRH analogs may examine receptor interactions, intracellular signaling, molecular stability, endocrine regulation, and analytical characterization.
These research areas contribute to the broader scientific understanding of peptide signaling and endocrine regulation. They should not be interpreted as evidence of established clinical benefits for the No DAC compound.
Why Peptide Identity Verification Matters
Peptides with similar names may have different molecular structures. For compounds associated with CJC-1295 research, the presence or absence of the DAC modification is a particularly important distinction.
Mass spectrometry can help determine whether a sample’s observed molecular mass is consistent with its intended identity. High-performance liquid chromatography may provide complementary information about chromatographic purity. Researchers should also examine peptide sequence, chemical modifications, batch identification, and analytical methods.
Research Limitations
Published research on DAC-containing CJC-1295 should be distinguished from research specifically involving the DAC-free analog. The two materials differ structurally, and findings involving the albumin-binding compound cannot automatically establish the behavior or safety profile of material marketed as CJC-1295 (No DAC).
The FDA has identified safety concerns associated with compounded CJC-1295, including potential immunogenicity and peptide-related impurity characterization challenges. Available clinical data are limited. These findings do not establish the safety of the No DAC compound. Further research is necessary under clearly defined experimental conditions.
The Azyven Research Perspective
Understanding peptide research begins with understanding molecular identity. CJC-1295 (No DAC) illustrates why closely related peptides must be evaluated according to their specific chemical structures rather than commercial names alone.
Through Peptide 101, Azyven Research explores scientific concepts behind research compounds, including receptor signaling, molecular modifications, and laboratory characterization. Our objective is to support informed scientific evaluation through accessible, research-focused educational content.
Research Use Only Disclaimer
This article is provided for educational and scientific informational purposes only. Research compounds discussed by Azyven Research are intended exclusively for laboratory research and are not intended for human or veterinary use, consumption, diagnosis, treatment, or prevention of disease.
Explore CJC-1295 (No DAC) for Research
Interested in working with CJC-1295 (No DAC) in your laboratory research? View Azyven Research CJC-1295 (No DAC) →
Available strengths and product information can be found on the product page.
For laboratory research use only.
References
1. Teichman, S. L., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/?term=Teichman+CJC-1295+2006
2. Mayo, K. E., et al. (1995). Growth hormone-releasing hormone: synthesis and signaling. https://pubmed.ncbi.nlm.nih.gov/7740167/
3. Signaling mechanism of growth hormone-releasing hormone receptor (2023). https://pubmed.ncbi.nlm.nih.gov/37717982/
4. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks